Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
ConclusionThis meta-analysis suggests that there is an association between statin use and decreased risk of cardiotoxicity after anthracycline and/or trastuzumab exposure. Larger well-conducted RCTs are needed to determine whether statins decrease risk of cardiotoxicity from anthracyclines and/or trastuzumab.Trial Registration Number and Date of RegistrationPROSPERO: CRD42020140352 on 7/6/2020.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cholesterol | Heart | Herceptin | Science | Statin Therapy | Study